Can Krystal Biotech (KRYS) Stock Reach $400?

Key Takeaways

• The central $400 target is the arithmetic mean of eight verifiable, current analyst price targets on Krystal Biotech, rounded from roughly $397.
• The latest verified share price is about $332, meaning reaching $400 would require a move of roughly 20%—a substantial, though not extreme, advance.
• Individual analyst targets span a wide $284 to $474 range, reflecting sharply different assumptions about pipeline and commercial execution.
• The strongest supports are growing revenue from the lead gene therapy Vyjuvek, an expanding international launch, and a deep clinical pipeline.
• The biggest risks are heavy reliance on a single product, unpredictable patient treatment patterns, reimbursement pressure, and binary clinical outcomes.
• Krystal Biotech is a commercial-stage gene therapy company, not an ETF, so this analysis centers on analyst price targets and company fundamentals.
• Readers can explore more detail on Major News, Today's Price Move, a Forecast, and Earnings for KRYS.
• For AI-driven market screening across stocks and ETFs, explore Trending AI Robots.

Analyst Price Targets and Consensus View

Krystal Biotech, Inc. (KRYS) carries a "Strong Buy" consensus rating from sell-side analysts. This central target is not a copied headline figure; it was calculated from eight individual, attributable targets reviewed for this analysis. The set spans roughly $284 to $474, with a simple arithmetic mean of about $397, rounded to a clean $400 central target.

Recent revisions cluster toward the upper half of the range. Citigroup raised its target to $416 from $386 in October 2026 after a clinical update, while Goldman Sachs resumed coverage with a $441 target in September. TD Cowen holds a $403 target, RBC Capital initiated at $400, and BofA raised its target to $400 from $392. Jefferies sits at the top with $474, while Guggenheim's $284 marks the low end, and H.C. Wainwright holds $361.

The wide dispersion reflects genuine disagreement: bullish analysts weight expanding commercial uptake and pipeline optionality, while cautious ones discount execution and pricing risk. The mean is a statistical summary, not a guarantee or an official published consensus.

Current Market Position and Path Toward the Target

With shares near $332, reaching $400 requires an approximate 20% upside—a substantial move by any measure. The stock has already re-rated meaningfully from a 52-week low around $137, reflecting a market cap near $9.8 billion as the company transitions from an early commercial launch to a multi-product, multi-market gene therapy franchise.

The path toward $400 would most plausibly rely on sustained revenue growth rather than multiple expansion alone. Krystal reported quarterly revenue of about $119 million for the period ending June 30, 2026, up from roughly $96 million a year earlier, with net profit also rising. International launches in Germany, France, and Japan, a UK marketing authorization secured in May 2026, and a planned Italy launch add incremental geographic runway. Continued clinical progress on programs such as the cystic fibrosis candidate KB407 and the alpha-1 antitrypsin deficiency candidate KB408 could justify higher valuations.

What Could Support a Move Toward the Target

• Vyjuvek momentum: the lead therapy for dystrophic epidermolysis bullosa has shown durable uptake, with over 660 U.S. reimbursement approvals and expanding international demand.
• Pipeline optionality: registrational-stage programs across cystic fibrosis, alpha-1 antitrypsin deficiency, ophthalmology, and oncology broaden the growth story beyond one drug.
• Analyst revisions: most recent target changes have been upward, and the stock was added to the S&P MidCap 400 index, a catalyst for institutional index demand.
• Balance sheet strength: the company held roughly $956 million in cash and investments at the end of fiscal 2025, funding research without immediate dilution pressure.

What Could Prevent the Target From Being Reached

• Single-product concentration: revenue remains heavily dependent on Vyjuvek, so any slowdown in patient starts or treatment persistence directly pressures results.
• Quarterly volatility: the chronic and variable nature of dystrophic epidermolysis bullosa leads to treatment pauses and restarts, reducing revenue predictability.
• Pricing and reimbursement: intensifying global pricing scrutiny on orphan and gene therapies could compress margins as the company expands internationally.
• Binary clinical risk: setbacks or delays in pipeline readouts could remove the very optionality underpinning the highest analyst targets.

Technical Levels and Market Structure

The stock trades below its 52-week high near $382.54, which sits between the current price and the $400 target and therefore represents a key near-term resistance zone. The $400 level itself is also a psychological round-number marker that may attract selling interest. The shares remain in a long-term uptrend off the 52-week low near $137, but the wide gap between the current price and that low underscores how far the stock has already traveled.

Time Horizon and What Investors Should Monitor

Most analyst price targets reflect a research horizon of roughly 12 months, though individual firms apply different assumptions and update timing. Investors should watch quarterly earnings and Vyjuvek revenue trends, reimbursement decisions in new European markets, and upcoming clinical readouts for KB407 and KB408. Changes in analyst targets—especially any move away from the recent upward revision pattern—would be an important signal, as would shifts in sector-wide sentiment toward gene therapy valuations.

AI Daily Buy/Sell Signals

For traders seeking a data-driven complement to fundamental research, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The platform helps users discover opportunities, monitor existing positions, and spot evolving trends more efficiently than manual screening alone. Explore these signals to add an objective, real-time layer to your own decision-making process.

Final Assessment

The $400 target represents a roughly 20% move from the current price near $332, built from the mean of eight verified analyst targets spanning $284 to $474. The case for reaching that level rests on continued Vyjuvek growth, international expansion, and pipeline progress, while the case against it hinges on single-product dependence, treatment-pattern volatility, reimbursement risk, and binary clinical outcomes. The unusually wide target range shows analysts genuinely disagree about how much of the pipeline to price in today. Whether KRYS closes the gap will depend most on execution in commercial markets and upcoming data readouts—outcomes that no price target can promise in advance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations